Preclinical evaluation of antigen-specific B-cell depletion for phospholipase A2 receptor membranous nephropathy with chimeric autoantibody receptor T cells
10.1016/j.kint.2025.09.028 · doi-reference
An antigen-specific chimeric autoantibody receptor (CAAR) NK cell strategy for the elimination of anti-PLA2R1 and anti-THSD7A antibody-secreting cells
10.1016/j.kint.2024.01.021 · doi-reference
Antigen-specific B cell depletion for precision therapy of mucosal pemphigus vulgaris
10.1172/jci138416 · doi-reference
Chimeric autoantibody receptor T cells clonally eliminate B cells producing autoantibodies against IFN-γ
10.1126/sciimmunol.adm8186 · doi-reference
Obinutuzumab in rituximab-resistant and recurrent membranous nephropathy: a case-series
10.1007/s40620-025-02224-6 · doi-reference
Obinutuzumab in kidney transplantation: past, present, and future
10.5500/wjt.v15.i4.108982 · doi-reference
Association of immunoglobulin levels, infectious risk, and mortality with rituximab and hypogammaglobulinemia
10.1001/jamanetworkopen.2018.4169 · doi-reference
Rituximab for severe membranous nephropathy: a 6-month trial with extended follow-up
10.1681/asn.2016040449 · doi-reference
Circulating (CD3(−)CD19(+)CD20(−)IgD(−)CD27(high)CD38(high)) plasmablasts: a promising cellular biomarker for immune activity for anti-PLA2R1 related membranous nephropathy?
10.1155/2016/7651024 · doi-reference
B- and T-cell subpopulations in patients with severe idiopathic membranous nephropathy may predict an early response to rituximab
10.1016/j.kint.2017.01.012 · doi-reference
B cell dysregulation and depletion therapy in primary membranous nephropathy: prospects and potential challenges
10.1016/j.intimp.2024.112769 · doi-reference
Prognostic value of PLA2R autoimmunity detected by measurement of anti-PLA2R antibodies combined with detection of PLA2R antigen in membranous nephropathy: a single-centre study over 14 years
10.1371/journal.pone.0173201 · doi-reference
Anti-PLA2R antibody levels and clinical risk factors for treatment nonresponse in membranous nephropathy
10.2215/cjn.0000000000000237 · doi-reference
A proposal for a serology-based approach to membranous nephropathy
10.1681/asn.2016070776 · doi-reference
The role of anti-PLA2R and anti-THSD7A antibodies in the pathogenesis and diagnostics of primary membranous nephropathy: a review of current knowledge for clinical practice
10.3390/ijerph19095301 · doi-reference
Pathophysiological advances in membranous nephropathy: time for a shift in patient's care
10.1016/s0140-6736(15)60731-0 · doi-reference
Treatment of membranous nephropathy: time for a paradigm shift
10.1038/nrneph.2017.92 · doi-reference
Anti-CD20 should be the first-line treatment in high-risk membranous nephropathy
10.1093/ckj/sfad075 · doi-reference
Efficacy and safety of zuberitamab in the treatment of primary membranous nephropathy: an observational study
10.3389/fimmu.2025.1741564 · doi-reference
Systematic review of safety and efficacy of second- and third-generation CD20-targeting biologics in treating immune-mediated disorders
10.3389/fimmu.2021.788830 · doi-reference
Successful treatment of PLA2R1-antibody positive membranous nephropathy with ocrelizumab
10.1007/s40620-020-00874-2 · doi-reference
Results of a phase I/II study of ocrelizumab, a fully humanized anti-CD20 mAb, in patients with relapsed/refractory follicular lymphoma
10.1093/annonc/mdq027 · doi-reference
The role of B lymphocyte subsets in nephrotic syndrome: functions, mechanisms, clinical significance and future perspectives
10.3389/fimmu.2025.1598197 · doi-reference
Implications of rituximab pharmacokinetic and pharmacodynamic alterations in various immune-mediated glomerulopathies and potential anti-CD20 therapy alternatives
10.3389/fimmu.2022.1024068 · doi-reference
Obinutuzumab and ofatumumab are more effective than rituximab in the treatment of membranous nephropathy patients with anti-rituximab antibodies
10.1016/j.ekir.2024.12.012 · doi-reference
Ofatumumab for multirelapsing membranous nephropathy complicated by rituximab-induced serum-sickness
10.1136/bcr-2019-232896 · doi-reference
The development of ofatumumab, a fully human anti-CD20 monoclonal antibody for practical use in relapsing multiple sclerosis treatment
10.1007/s40120-023-00518-0 · doi-reference
Anti-CD20 monoclonal antibodies: reviewing a revolution
10.1080/21645515.2018.1508624 · doi-reference
Observation of the efficacy and safety of obinutuzumab in the treatment of refractory idiopathic membranous nephropathy
10.1007/s11255-025-04407-3 · doi-reference
Obinutuzumab is effective as an initial treatment for PLA2R-associated primary membranous nephropathy: a retrospective, single-center trial
10.2147/dddt.s527661 · doi-reference
Treatment resistant M-type phospholipase A2 receptor associated membranous nephropathy responds to obinutuzumab: a report of two cases
10.1186/s12882-022-02761-3 · doi-reference
Obinutuzumab is effective for the treatment of refractory membranous nephropathy
10.1016/j.ekir.2020.06.030 · doi-reference
Obinutuzumab versus rituximab for the treatment of refractory primary membranous nephropathy
10.1093/ndt/gfae230 · doi-reference
Comparison of obinutuzumab and rituximab for treating primary membranous nephropathy
10.2215/cjn.0000000000000555 · doi-reference
Targeting B cells and plasma cells in glomerular diseases: translational perspectives
10.1681/asn.2017040367 · doi-reference
Efficacy and safety of obinutuzumab in active lupus nephritis
10.1056/nejmoa2410965 · doi-reference
The future of anti-CD20 monoclonal antibodies: are we making progress?
10.1182/blood-2010-07-298356 · doi-reference
Preclinical activity of the type II CD20 antibody GA101 (obinutuzumab) compared with rituximab and ofatumumab in vitro and in xenograft models
10.1158/1535-7163.mct-12-1182 · doi-reference
Increasing the efficacy of CD20 antibody therapy through the engineering of a new type II anti-CD20 antibody with enhanced direct and immune effector cell-mediated B-cell cytotoxicity
10.1182/blood-2009-06-225979 · doi-reference
Successful treatment of patients with refractory PLA2R-associated membranous nephropathy with obinutuzumab: a report of 3 cases
10.1053/j.ajkd.2020.02.444 · doi-reference
